Non-Engineered Physiologically Modulated Nanovesicles Augment Antitumor Immune Responses via Dual-Pathway T Cell...

Area of Science:

• Immunology
• Nanotechnology
• Oncology

Background:

• Cancer vaccine efficacy relies on CD8+ T cell immunity, but T cell activation is often insufficient.
• Existing cancer immunotherapies face challenges in achieving robust and durable T cell responses.

Purpose of the Study:

• To develop a novel nanovaccine platform, ASCENT, that enhances CD8+ T cell activation for improved cancer immunotherapy.
• To leverage naturally occurring cellular components for antigen and co-stimulatory molecule presentation without genetic engineering.

Main Methods:

• ASCENT nanovaccine was engineered using nanovesicles from activated platelets and senescent tumor cells.
• Senescent tumor cells were utilized for antigen presentation via MHC-I molecules.
• Activated platelets provided co-stimulatory molecules (CD40L, OX40L) to enhance immune activation.

Main Results:

• ASCENT effectively stimulated CD8+ T cells through both direct antigen self-presentation and dendritic cell-mediated presentation.
• The nanovaccine demonstrated broad-spectrum antitumor activity in preclinical models.
• ASCENT induced durable systemic immune memory, suppressing tumor recurrence and metastasis.

Conclusions:

• The ASCENT nanovaccine platform offers a non-engineered approach to enhance cancer immunotherapy by dual-pathway T cell activation.
• This strategy highlights the importance of engaging both direct and indirect T cell activation for effective cancer treatment.
• ASCENT provides a promising new direction for rational cancer vaccine design.